President Donald Trump signed an executive order on April 18 that will establish a pathway that gives people with mental illnesses access to psychedelic drugs, including ibogaine compounds.
The executive order signed on Saturday morning aimed to accelerate research and approval of psychedelic drugs that could save lives and help reverse the mental illness plaguing America, according to the order.
